Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant pegylated liposomal doxorubicin + docetaxel + trastuzumab for HER2-positive breast cancer
ChiCTR1900021473Phase 4Recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Feb 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of doxorubicin, docetaxel and trastuzumab in breast cancer, sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: Pathologic complete response rate. Started Feb 2019; status: recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR1900021473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021473.